ANTOINETTE BURKE: Open Payments
NPI 1982078531 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$660 in 24 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $660
Food & beverage: $660
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 5 | $145 |
| Novartis Pharmaceuticals Corporation | 6 | $142 |
| Amgen Inc. | 4 | $106 |
| Regeneron Healthcare Solutions, Inc. | 2 | $78 |
| LEO Pharma Inc. | 2 | $51 |
| Grifols USA, LLC | 1 | $37 |
| AstraZeneca Pharmaceuticals LP | 1 | $31 |
| Arcutis Biotherapeutics, Inc. | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| CSL Behring | 1 | $22 |
Products named: DUPIXENT, TEZSPIRE, XOLAIR, ADBRY, Rhapsido, Xembify, Zoryve, TRELEGY ELLIPTA.
Industry payments across CA — which companies pay providers there.
